Abstract:
AIM:To assess the potential differences in the metabolic and cardiovascular disease (CVD) risk between the distinct phenotypes of the Polycystic Ovary Syndrome (PCOS) according to the Rotterdam definition regardless of body mass index (BMI). PATIENTS-METHODS:The study included 300 women; 240 women with PCOS, according to the Rotterdam criteria and 60 controls without PCOS. All women were further subdivided, according to their BMI, into normal-weight and overweight/obese and PCOS women were furthermore subdivided to the 4 phenotypes of the syndrome. A complete hormonal and metabolic profile as well as the levels of high sensitivity C reactive protein (hsCRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured. OUTCOMES:Levels of surrogate markers of subclinical atherosclerosis (hsCRP and Lp-PLA2), levels of evaluated CVD risk score using risk engines, and several correlations of CVD risk factors. RESULTS:hsCRP levels were higher but not significantly so in PCOS women compared with controls. In lean PCOS patients, Lp-PLA2 levels were significantly higher, compared with lean controls, mainly in the 2 classic phenotypes. Overweight/obese patients in all 4 phenotypes had significantly higher Lp-PLA2 levels compared with overweight/obese controls. Evaluated CVD risk according to 4 risk engines was not different among phenotypes and between PCOS patients and controls. There were several correlations of risk factors with metabolic syndrome and non-alcoholic fatty liver disease requiring appropriate treatment. CONCLUSION:Only 2 of 4 Rotterdam phenotypes, identical with those of the classic PCOS definition, have excess cardiometabolic risk. These need to be treated to prevent CVD events.
journal_name
Curr Vasc Pharmacoljournal_title
Current vascular pharmacologyauthors
Daskalopoulos G,Karkanaki A,Piouka A,Prapas N,Panidis D,Gkeleris P,Athyros VGdoi
10.2174/1567201812666150120163025subject
Has Abstractpub_date
2015-01-01 00:00:00pages
788-800issue
6eissn
1570-1611issn
1875-6212pii
CVP-EPUB-64707journal_volume
13pub_type
临床试验,杂志文章abstract::Central arterial systolic blood pressure is a very important factor in the pathophysiology of cardiovascular diseases. Central arterial pressure is a better predictor of cardiovascular risk than peripheral brachial blood pressure. Measurement of central blood pressure is useful for a diagnosis of spurious systolic hyp...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110793563852
更新日期:2010-11-01 00:00:00
abstract::Cardiovascular disease (CVD) is among the most major causes of morbidity and mortality worldwide. Great progress has been made in the management of CVD which has been influenced by the use of experimental animal models. These models provided information at cellular and molecular levels and allowed the development of t...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161113666150212151506
更新日期:2015-01-01 00:00:00
abstract::A considerable amount of data supports a 1.8-7.4-fold increased mortality associated with Cushing's syndrome (CS). This is attributed to a high occurrence of several cardiovascular disease (CVD) risk factors in CS [e.g. adiposity, arterial hypertension (AHT), dyslipidaemia and type 2 diabetes mellitus (T2DM)]. Therefo...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161116666181005122339
更新日期:2020-01-01 00:00:00
abstract::Non-fasting triglycerides are measured at any time within up to 8 h (14 h) after any normal meal, while postprandial triglycerides are measured at a fixed time point within up to 8 h (14 h) of a standardised fat tolerance test. The simplest possible way of evaluating remnant cholesterol is non-fasting/postprandial tot...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016111795495585
更新日期:2011-05-01 00:00:00
abstract:BACKGROUND:Add-on therapy with the Mineralocorticoid-Receptor-Antagonists (MRAs) spironolactone and eplerenone was shown to enhance the cardioprotective action of angiotensinconverting- enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and/or β-blockers in nondialysis patients with congestive heart failur...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161115666170201113817
更新日期:2017-01-01 00:00:00
abstract::This review considers drug combinations and newer treatment strategies for patients with severe hypertriglyceridemia. Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk. Patients with severe hypertriglyceridemia also have increased in...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/15701611113119990133
更新日期:2014-01-01 00:00:00
abstract::In the last decade there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VA) and Sudden Cardiac Death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016109788340794
更新日期:2009-07-01 00:00:00
abstract::Arterial stiffness (AS) is considered an independent predictor of cardiovascular disease (CVD) events. Among lipid lowering drugs, statins have a beneficial effect on AS, independent of their hypolipidaemic effect. Based on 3 meta-analyses and other studies, this effect is compound- and doserelated. Potent statins at ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161117666190121102323
更新日期:2020-01-01 00:00:00
abstract::Neuropathies of the peripheral and autonomic nervous systems affect up to half of all people with diabetes mellitus, and are major risk factors for foot ulceration, amputation and cardiovascular dysfunction. Peripheral neuropathies manifest with either painful or painless symptoms, but many patients experience both. O...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161117666190521101342
更新日期:2020-01-01 00:00:00
abstract::The hypothesis of 'Developmental Origins of Health and Disease' (DOHaD) relies on the presence of mechanisms sensing and signalling a diversity of stimuli during fetal development. The mechanisms that have been broadly suggested to be involved in these processes are the epigenetic modifications that could 'record' per...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016109789043883
更新日期:2009-10-01 00:00:00
abstract:OBJECTIVE:To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment. METHODS:Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2174/1570161112666141014151858
更新日期:2015-01-01 00:00:00
abstract::Recent updates in the field of echocardiography have resulted in improvements in both image quality and techniques allowing echocardiography to maintain its position as the primary non-invasive imaging modality. In particular, the development of new ultrasound contrast agents and imaging techniques have now made possi...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016106777698423
更新日期:2006-07-01 00:00:00
abstract::Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldos...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016112799304969
更新日期:2012-03-01 00:00:00
abstract::Obesity and Gestational Diabetes Mellitus (GDM) are the most frequent pathologies affecting mothers and offspring during pregnancy. Both conditions have shown a sustained increase in their prevalence in recent years, and they worsen the outcome of pregnancy and the long-term health of mothers. Obesity increases the ri...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161118666200628142353
更新日期:2021-01-01 00:00:00
abstract:BACKGROUND:Single-pill fixed dose combination (FDC) therapies are widely used in the treatment of arterial hypertension. OBJECTIVE:This pilot study aimed to evaluate the effects of a FDC therapy combined with therapeutic drug monitoring (TDM) on blood pressure (BP) in patients with treatment resistant hypertension. M...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161115666170821155555
更新日期:2018-01-26 00:00:00
abstract::An inverse association between diabetes mellitus (DM) and abdominal aortic aneurysm (AAA) risk have been reported. Apart from a lower AAA prevalence among patients with vs without DM, there are data showing that DM may exert a protective role on aneurysmal growth in patients with small AAAs, thus decreasing the risk o...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161113666150529125127
更新日期:2016-01-01 00:00:00
abstract::Epidemiological evidence supports a reduced prevalence of Thoracic Aortic Aneurysm (TAA) and Abdominal Aortic Aneurysm (AAA) in patients with Diabetes (DM). The mechanisms underlying this negative association are unknown. Some studies support that hyperglycemia has effects on the Extracellular Matrix (ECM), resulting ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161116666180828155622
更新日期:2019-01-01 00:00:00
abstract::Initially, the progression of chronic venous insufficiency is related to venous hypertension. The earliest complaints or symptoms, as well as vessel wall deterioration, valve restructuring, and, eventually, varicose veins, result not only from elevation of pressure, but also from a cascade of biochemical events relate...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161052773870
更新日期:2005-01-01 00:00:00
abstract::Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016110792006923
更新日期:2010-09-01 00:00:00
abstract::Aspirin plays a pivotal role in the management of patients with Coronary Artery Disease (CAD) with well-recognised benefits of reducing recurrent myocardial infarction and minimising the risk of stent thrombosis for those undergoing Percutaneous Coronary Intervention (PCI). Dual antiplatelet therapy is mandated for pa...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/1570161116666180604100220
更新日期:2019-01-01 00:00:00
abstract::In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...
journal_title:Current vascular pharmacology
pub_type: 评论,社论
doi:10.2174/157016112803520783
更新日期:2012-11-01 00:00:00
abstract::We evaluated the effects of the glycosaminoglycan sulodexide (SDX; antithrombotic/profibrinolytic drug) on the activity and release of matrix metalloproteinases (MMPs) in human blood. This was a prospective non-randomized study, analyzing by zymography and ELISA the in vitro effects of SDX on pro-enzyme, complexed, an...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161111311030010
更新日期:2013-05-01 00:00:00
abstract:BACKGROUND:Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. METHOD:A multicentre, non-interventional survey conducted in 6 Middle Eastern cou...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,多中心研究
doi:10.2174/1570161115666170705153815
更新日期:2018-01-01 00:00:00
abstract::Cardiovascular failure in sepsis involves a combination of hypovolemia, decreased vascular tone, myocardial depression and microcirculatory alterations. Fluids represent the first line therapeutic intervention, with controversy regarding the type of fluid. Recent data indicate that albumin is safe and might even be be...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:
更新日期:2013-03-01 00:00:00
abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), are major health problems worldwide. Genetics may play a role in the pathogenesis of NAFLD/NASH. AIM:To investigate the prevalence of NAFLD/NASH in 5,400 military personnel and evaluate the effect of treatme...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161118666201015152921
更新日期:2020-10-15 00:00:00
abstract:BACKGROUND:We described lifestyle changes one year after acute coronary syndrome (ACS) among patients in Arabian Gulf countries. METHODOLOGY:Data of patients admitted to 29 hospitals in 4 countries with the diagnosis of ACS were analysed from Gulf citizens with ACS events (Gulf COAST) registry. A total of 3565 ACS pat...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,多中心研究
doi:10.2174/1570161115666170529090700
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:Atherosclerosis is a multifactorial inflammatory disease of the cardiovascular system. It has been suggested that periodontitis, an infectious disease of oral cavity caused by gramnegative anaerobic bacteria, could be linked to atherosclerosis. OBJECTIVE:The objective of this systematic review was to assess...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161115666170830141852
更新日期:2018-01-01 00:00:00
abstract::In recent years, the development of more effective drugs has provided a better prognosis and an increase in life expectancy for patients at all-stages of cancer. On the other hand, the price for the improving effectiveness of therapies against malignant tumors is the development of severe and potentially life-threaten...
journal_title:Current vascular pharmacology
pub_type: 杂志文章,评审
doi:10.2174/157016111201140327163302
更新日期:2014-01-01 00:00:00
abstract::In end-stage renal disease patients, the leading causes of mortality are of cardiovascular (CV) origin. The underlying mechanisms are complex, given that sudden heart failure is more common than acute myocardial infarction. A contributing role of oxidative stress is postulated, which is increased even at early stages ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161118666200317151553
更新日期:2021-01-01 00:00:00
abstract:: ...
journal_title:Current vascular pharmacology
pub_type: 杂志文章
doi:10.2174/1570161117999190403163922
更新日期:2019-01-01 00:00:00